Fluidigm Highlights New Advancements in Deep Cellular Profiling from Circulation to Tissue at CYTO 2019
“The progress being made to advance our understanding of health and disease using CyTOF® technology has been truly impressive. Now used in more than 40 clinical research trials and by multiple consortia around the world, CyTOF technology is offering new insights in cancer, autoimmune and infectious disease, neurological disorders and more,” said
Featured Immunology and Immunotherapy Research Applications
- Setting an industry first for highly multiplexed cytometry, mass cytometry has enabled researchers to simultaneously interrogate more than 50 cell surface and intracellular parameters at a time, all from a single sample tube. By providing 135 unique channels to detect different cellular parameters, Fluidigm® mass cytometry systems can meet the needs of researchers today and well into the future. Seven new cadmium metal labeling kits planned for release in the third quarter will be showcased, empowering researchers to easily design and customize large panels to advance biomarker discovery and therapeutic development.
- Introducing the new standard in immune profiling, the
FluidigmMaxpar® Direct™ Immune Profiling System is the first complete sample-to-answer solution for deep human immune cell profiling using mass cytometry. Developed for use with Helios™, a CyTOF system, it empowers researchers to quantify 37 different immune cell populations from human peripheral blood mononuclear cells (PBMC) and whole blood using a simple single-tube workflow with automated five-minute results reporting.
Monday, June 24, Stephen Li, PhD, of Fluidigmwill present results on the analytical validation of the Maxpar Direct Immune Profiling System in a poster titled A Robust Human Immunophenotyping Workflow Using Maxpar® Direct™ Immune Profiling Assay™ Coupled with Maxpar Pathsetter™, an Automated Data Analysis Solution for Mass Cytometry. Additional presentations on the Maxpar Direct Immune Profiling System will be given daily at Fluidigm Booth 426 from Sunday, June 23, to Wednesday, June 26.
- Imaging Mass Cytometry™ is powering new breakthroughs globally with more than 25 scientific publications and an established footprint of more than 50 commercially enabled systems in more than 10 countries. Ideal for deep cellular phenotyping in tissue and tumor microenvironments, the Hyperion™ Imaging System enables simultaneous imaging of up to 37 protein markers from a single scan of formalin-fixed, paraffin-embedded (FFPE) or fresh tumor sections. Exciting new CyTOF Software enhancements that streamline the acquisition of multiple regions of interest from each slide and guide automated batch acquisition of highly multiplexed images at 1-micron resolution will be highlighted.
- Three new Imaging Mass Cytometry Maxpar panel kits for immuno-oncology will be showcased. Developed using pathologist-verified antibodies, the panels can be mixed and matched to profile tumor-infiltrating lymphocytes, immune cell activation states and tissue architecture. By combining them as a single 18-marker panel, researchers can broadly profile activated tumor-infiltrating lymphocytes for single-cell analysis of the tumor architecture, all from a single tissue scan. Customization is also simplified using CyTOF technology, enabling researchers to easily add more than 10 markers to support specific translational and clinical research studies. The panel kits will be available for sale in the third quarter.
Monday, June 24, Dongxia Lin, PhD, of Fluidigmwill present highly-multiplexed imaging results using a 27-marker panel containing structural, cancer, and immuno-oncology markers in a poster titled Exploring Healthy and Tumor Tissue Microenvironments with Immuno-Oncology Markers Using Multiplexed Analysis on the Hyperion Imaging System. Additional presentations will be given daily at Fluidigm Booth 426 from Sunday, June 23, to Wednesday, June 26.
CYTO 2019 Tutorial
During the meeting, researchers from leading cancer centers and academic medical centers will share more than 70 presentations and posters using
Atul Butte, MD, PhD, Director of the Bakar Computational Health Sciences Instituteat the University of California, San Francisco, and Chief Data Scientist for University of California Health System, will present new research studies of immunology, therapies and diagnostics based on the translation of a trillion points of data on June 23. Jonathan Irish, PhD, Assistant Professor, Department of Cell and Developmental Biology at Vanderbilt University School of Medicine, will present an analysis of single-cell interrogation of phosphoprotein signaling that successfully revealed novel leukemia and lymphoma cell types on June 24. Alice Wiedeman, PhD, of the Benaroya Research Instituteat Virginia Mason, will present an analysis of rare autoreactive T cells in type 1 diabetes using CyTOF plus DISCOV-R on June 26.
More information on the
8th Annual Fluidigm Mass Cytometry Summit
In advance of CYTO 2019,
Forward-Looking Statement for
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of newly introduced products and the growth and potential of immune profiling and
Senior Director, Marketing
650 737 4190
Vice President, Investor Relations
650 416 7423
Source: Fluidigm Corporation